Vanguard Global Advisers
ALLO icon

Vanguard Global Advisers’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Global Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
215,185
+111,938
+108% +$246K ﹤0.01% 2154
2026
Q1 		$252K Buy
+103,247
New +$207K ﹤0.01% 2327

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Global Advisers's ALLO Position: Q2 2026 in Review

Vanguard Global Advisers increased its Allogene Therapeutics (ALLO) stake by 108% in Q2 2026, buying an estimated $246K and bringing the position to 215,185 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Vanguard Global Advisers first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vanguard Global Advisers held 215,185 shares of Allogene Therapeutics worth $448K as of Q2 2026.
  • Vanguard Global Advisers bought 111,938 Allogene Therapeutics shares in Q2 2026, an estimated $246K.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2154 holding.
  • Vanguard Global Advisers first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.